Upregulation of YY1 / EZH2 and MLH1 as Therapeutic Targets for Adult T‐Cell Leukemia/Lymphoma
Cancer Science · 2025-08 · 116 (8) · 2163-2175
DOI: 10.1111/cas.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 12.05.2025. Verfasst von Takuya Shimizu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: YY1 Transcription Factor, Leukemia-Lymphoma, Adult T-Cell, Enhancer of Zeste Homolog 2 Protein, MutL Protein Homolog 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Uehara Memorial Foundation, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
The clinical and genetic presentation of adult T‐cell leukemia/lymphoma (ATLL) ranges from indolent to aggressive, making it difficult to identify common therapeutic targets. Inhibiting EZH1/2 suppresses ATLL through epigenetic modulation; however, the diverse genetic background of ATLL precludes its mode of action from being clearly elucidated. We conducted single‐cell RNA sequencing (scRNA‐seq) of primary ATLL cells and identified an epigenetic regulative axis. First, flow cytometry showed that the proliferative potential of CADM1 + HTLV‐1‐infected cells ranges from stable to treatment‐required. Second, scRNA‐seq identified a CCR4 + CD48 − cluster, the population of which increased in treatment‐required patients. In silico promoter analysis of this cluster identified a transcription factor YY1 as a candidate regulator. Intracellular flow cytometry confirmed that YY1 and EZH2 were upregulated in acute‐type. By contrast, MLH1 but not MSH2 within CADM1 + cells was downregulated in remitted ATLL ( p < 0.05), suggesting that MLH1 is associated with YY1/EZH2. Notably, lentiviral YY1 knockdown and the EZH1/2 inhibitor valemetostat downregulated MLH1 in ATLL cell lines and primary ATLL cells. Finally, knockdown of YY1 or MLH1 suppressed the proliferation of ATLL cells. Our findings suggest that YY1/EZH2 overexpression in the ATLL subpopulation defines aggressiveness and that MLH1 downregulation through YY1/EZH2 inhibition may be an effective treatment for aggressive ATLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Hematology/Oncology, Hiroshima University Research Institute for Radiation Biology and Medicine, Hiroshima, Japan.
- CyberomiX, Inc., Kyoto, Japan.
- Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
ORCID-Profile: Takero Shindo
Förderung
- Japan Society for the Promotion of Science
- Uehara Memorial Foundation
- Japan Agency for Medical Research and Development
Zitieren
APA
Shimizu, T., Shindo, T., Ogawa, H., Teranaka, K., Watanabe, A., & Takaori-Kondo, A. (2025). Upregulation of YY1 / EZH2 and MLH1 as Therapeutic Targets for Adult T‐Cell Leukemia/Lymphoma. Cancer Science, 116(8), 2163-2175. https://doi.org/10.1111/cas.70095
Vancouver
Shimizu T, Shindo T, Ogawa H, Teranaka K, Watanabe A, Takaori-Kondo A. Upregulation of YY1 / EZH2 and MLH1 as Therapeutic Targets for Adult T‐Cell Leukemia/Lymphoma. Cancer Science. 2025;116(8):2163-2175. doi:10.1111/cas.70095
BibTeX
@article{Shimizu2025,
author = {Shimizu, Takuya and Shindo, Takero and Ogawa, Hanako and Teranaka, Kaori and Watanabe, Akira and Takaori-Kondo, Akifumi},
title = {Upregulation of YY1 / EZH2 and MLH1 as Therapeutic Targets for Adult T‐Cell Leukemia/Lymphoma},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {8},
pages = {2163--2175},
doi = {10.1111/cas.70095}
}
EUVIMED